The payment from EOC Pharma, an oncology focused affiliate of Eddingpharm, relates to the development of eftilagimod alpha in China.
It follows the granting of EOC Pharma’s Investigational New Drug (IND) application in China.
Eftilagimod alpha is a first-in-class soluble LAG-3Ig fusion protein that is also an antigen presenting cell activator.
Investigated in clinical trials
It is being investigated in clinical trials as a treatment, in combination with chemotherapy or immune therapy, for breast cancer and melanoma.
In May 2013, Immutep and Eddingpharm entered into a licensing agreement granting Eddingpharm exclusive development rights for eftilagimod in China, including Hong Kong, Macau, and Taiwan.
In January 2015, the licence was transferred from Eddingpharm to EOC Pharma upon the consent of Immutep.
Required to make milestone payments
In exchange, EOC Pharma agreed to pay for the manufacturing of certain drug supply for Immutep and is required to make milestone payments if eftilagimod achieves specified development milestones.
EOC Pharma will also pay Immutep a royalty on net sales of eftilagimod in China, if approved.
Immutep is a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease.
Leader in developing LAG-3 products
It is a leader in the understanding and development of therapies that modulate Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule which plays a vital role in regulating T cells.
A number of Immutep’s additional LAG-3 products, including antibodies for immune response modulation in autoimmunity and cancer, are being developed by large pharmaceutical partners.